UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE:CI) with a price target of $390. Rice shared his views ...

To mitigate this risk, Cigna will need to focus on effective cost management strategies, such as negotiating favorable contracts with drug manufacturers ... landscape or pricing pressures could ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

On Friday, UBS analyst AJ Rice confirmed a Buy rating for Cigna (NYSE: CI) shares, maintaining the $390.00 price target.Rice provided insights following a recent investor event at the Evernorth ...

Healthcare has been running neck and neck with energy and consumer discretionary for the worst sector of 2025.

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...

We can move toward free market reforms in drug pricing. We must overturn the current perverse incentives that favor the ...

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated ...

CVS Health CVS and The Cigna Group CI stand as two dominant forces in the U.S. diversified healthcare sector, commanding ...

The MD of the insurance broking firm also says that life insurance companies are likely to continue scaling back their ...

Cigna’s latest SWOT analysis shows a company flexing its market muscles despite tricky healthcare headwinds. Cigna’s strong ...